Arrowhead Research (NASDAQ:ARWR)
was one of the top performers on Thursday morning following publication
of results of a clinical study into its hepatitis B drug, ARC-520.
Investors clambered aboard as Arrowhead unveiled the top-line
findings from the Heparc-2001 Phase 2a clinical study of ARC-520, which
is designed to treat chronic hepatitis B infection by inhibiting the
production of all HBV gene products.
The study indicated the drug can effectively and consistently knock down target genes in humans that are HBV E-antigen positive.
To date, 84 humans have received ARC-520 and no adverse events have
been rated as serious or severe, no discontinuations have occurred due
to an adverse event, and no laboratory results have indicated any end
organ toxicity, Arrowhead revealed.
Additionally, nine chimps received six-11 monthly doses of ARC-520 and no safety signals were detected in any chimp.
“These are exciting data that represent a significant leap forward
for our DPC platform, ARC-520, and the HBV field,” said Christopher
Anzalone, president and chief executive officer of Arrowhead.
“We have achieved the highest knock-down ever reported in humans with
RNAi and a safety profile that continues to be excellent. We are
optimistic that this will ultimately translate into powerful clinical
outcomes for ARC-520 and follow-on candidates against multiple
indications,” he added.
Shares rose US$1.23 to US$7.97 in the morning session.
Source: http://beforeitsnews.com/financial-markets/2015/09/arrowhead-research-on-target-with-hepatitis-b-candidate-2846000.htmlLabels: ARC-520, Heparc-2001 Phase 2a clinical study of ARC-520